



# GLAND PHARMA LIMITED

August 02, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Conclusion of US FDA Un-announced Inspection at Pashamylaram Facility, Hyderabad**

This is to inform you that the United States Food and Drug Administration (US FDA) has conducted an un-announced inspection of the Company's Pashamylaram Facility at Hyderabad for Good Manufacturing Practices (GMP) between 25<sup>th</sup> July, 2024 and 02<sup>nd</sup> August, 2024.

The said inspection was concluded with THREE (3) 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.

Request to take the above information on record.

Yours truly,

**For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi**  
**Company Secretary & Compliance Officer**